A small number of case reports regarding the use of kinase inhibitors in patients with FGFR3-TACC3 fusion-positive glioblastomas exists: Wang et al. treated two patients with the kinase inhibitor anlotinib [97]. This evidence concerns the gene TACC3 and glioblastoma.